On an annual basis, sales fell from KRW 69 billion in 2022 to KRW 30.8 billion in 2023 (down 55.4% year on year) and to KRW 25 billion in 2024 (down 18.7%), before edging up to KRW 25.6 billion in 2025 (up 2.2%). 2022 was the largest year in the 2022 to 2025 period and 2024 the smallest.
Profitability fell much further than sales. The operating margin moved from 22.8% in 2022 to -4.3% in 2023, -12.5% in 2024 and -9.2% in 2025.
The KRW 15.7 billion operating profit of 2022 turned into an operating loss of KRW 1.34 billion in 2023, widened to KRW 3.13 billion in 2024, and narrowed to KRW 2.36 billion in 2025.
Attributable net income fell from KRW 13.2 billion in 2022 to KRW 646 million in 2023 (down 95.1%), then turned into an attributable net loss of KRW 2.84 billion in 2024 and KRW 1.64 billion in 2025.
Net income including non-controlling interests, which differs from attributable net income, was a net loss of KRW 2.84 billion in 2024 and KRW 1.64 billion in 2025.
Operating cash flow moved from KRW 24.4 billion in 2022 to negative figures of -KRW 2.55 billion in 2023, -KRW 1.73 billion in 2024 and -KRW 1.56 billion in 2025.
The debt ratio declined from 50.8% in 2022 to 24.1% in 2025, with total equity of KRW 42.3 billion and total liabilities of KRW 10.2 billion at year-end 2025.
Quarterly, sales were KRW 6.87 billion in the third quarter of 2025 with an operating loss of KRW 586 million, then KRW 6.27 billion in the fourth quarter (down 8.8% quarter on quarter) with an operating loss of KRW 857 million, and KRW 6.98 billion in the first quarter of 2026 (up 11.4%) with an operating loss of KRW 1.59 billion.
According to the company's briefing material, first-quarter selling and administrative expenses included one-off integration and restructuring costs tied to the launch of ZGOO Holdings and the acquisition of a clinical trial subsidiary, while non-operating items included a KRW 990 million valuation gain on listed shares it holds.
Second-quarter 2026 sales rose to KRW 12 billion (up 72.1%) and the operating loss narrowed to KRW 549 million. Third-quarter sales were KRW 10.7 billion (down 11.0% quarter on quarter, up 55.6% year on year), but the operating loss widened to KRW 2.22 billion from the second quarter.
The attributable net loss narrowed to KRW 2.28 billion in the third quarter from KRW 3.7 billion in the second quarter.